Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations. Fluoropyrimidines have lon...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2015-05, Vol.372 (20), p.1909-1919 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1919 |
|---|---|
| container_issue | 20 |
| container_start_page | 1909 |
| container_title | The New England journal of medicine |
| container_volume | 372 |
| creator | Mayer, Robert J Van Cutsem, Eric Falcone, Alfredo Yoshino, Takayuki Garcia-Carbonero, Rocio Mizunuma, Nobuyuki Yamazaki, Kentaro Shimada, Yasuhiro Tabernero, Josep Komatsu, Yoshito Sobrero, Alberto Boucher, Eveline Peeters, Marc Tran, Ben Lenz, Heinz-Josef Zaniboni, Alberto Hochster, Howard Cleary, James M Prenen, Hans Benedetti, Fabio Mizuguchi, Hirokazu Makris, Lukas Ito, Masanobu Ohtsu, Atsushi |
| description | TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations.
Fluoropyrimidines have long represented the cornerstone of treatment for colorectal cancer.
1
Such compounds act primarily as inhibitors of thymidylate synthase, the rate-limiting enzyme in the synthesis of pyrimidine nucleotides.
2
Fluorouracil has been combined with folinic acid (also known as leucovorin) to enhance the capacity of fluorouracil to bind to thymidylate synthase.
2
The addition of irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) to fluorouracil and folinic acid, in combination with either a vascular endothelial growth factor inhibitor (bevacizumab) or an epidermal growth factor inhibitor (e.g., cetuximab or panitumumab) if the tumor contains a wild-type
RAS
gene, represents contemporary standard therapy and has extended . . . |
| doi_str_mv | 10.1056/NEJMoa1414325 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01152847v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3685405121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-c0036a1d615b732977bffbb822d7a5e92010f6ed840292682faba47c0ff6c8eb3</originalsourceid><addsrcrecordid>eNp10c9LwzAUB_Agis7p0asURNBD9b00SdvjGPMXm4LOc0jTBDvaRpNOmH-9HVNBwVwehA9f3g9CjhAuELi4vJ_czZxChiyhfIsMkCdJzBiIbTIAoFnM0jzZI_shLKB_yPJdskd5ngJwGJDrR9WWrqk-TBnNfaXqyNloPnqKEWhknY8ejfVKd86vopnpVOhUV-lo7Grnje56P1atNv6A7FhVB3P4VYfk-WoyH9_E04fr2_FoGmuesC7WAIlQWArkRZrQPE0La4sio7RMFTc5BQQrTJkxoDkVGbWqUCzVYK3QmSmSITnf5L6oWr76qlF-JZ2q5M1oKtd_gMhpxtJ37O3Zxr5697Y0oZNNFbSpa9UatwwSRYZUIO1XNyQnf-jCLX3bT7JWkOd9N-vAeKO0dyF4Y386QJDra8hf1-j98VfqsmhM-aO_19-D0w1omiBbs2j-CfoEJQyMyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1680992921</pqid></control><display><type>article</type><title>Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Mayer, Robert J ; Van Cutsem, Eric ; Falcone, Alfredo ; Yoshino, Takayuki ; Garcia-Carbonero, Rocio ; Mizunuma, Nobuyuki ; Yamazaki, Kentaro ; Shimada, Yasuhiro ; Tabernero, Josep ; Komatsu, Yoshito ; Sobrero, Alberto ; Boucher, Eveline ; Peeters, Marc ; Tran, Ben ; Lenz, Heinz-Josef ; Zaniboni, Alberto ; Hochster, Howard ; Cleary, James M ; Prenen, Hans ; Benedetti, Fabio ; Mizuguchi, Hirokazu ; Makris, Lukas ; Ito, Masanobu ; Ohtsu, Atsushi</creator><creatorcontrib>Mayer, Robert J ; Van Cutsem, Eric ; Falcone, Alfredo ; Yoshino, Takayuki ; Garcia-Carbonero, Rocio ; Mizunuma, Nobuyuki ; Yamazaki, Kentaro ; Shimada, Yasuhiro ; Tabernero, Josep ; Komatsu, Yoshito ; Sobrero, Alberto ; Boucher, Eveline ; Peeters, Marc ; Tran, Ben ; Lenz, Heinz-Josef ; Zaniboni, Alberto ; Hochster, Howard ; Cleary, James M ; Prenen, Hans ; Benedetti, Fabio ; Mizuguchi, Hirokazu ; Makris, Lukas ; Ito, Masanobu ; Ohtsu, Atsushi ; RECOURSE Study Group</creatorcontrib><description>TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations.
Fluoropyrimidines have long represented the cornerstone of treatment for colorectal cancer.
1
Such compounds act primarily as inhibitors of thymidylate synthase, the rate-limiting enzyme in the synthesis of pyrimidine nucleotides.
2
Fluorouracil has been combined with folinic acid (also known as leucovorin) to enhance the capacity of fluorouracil to bind to thymidylate synthase.
2
The addition of irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) to fluorouracil and folinic acid, in combination with either a vascular endothelial growth factor inhibitor (bevacizumab) or an epidermal growth factor inhibitor (e.g., cetuximab or panitumumab) if the tumor contains a wild-type
RAS
gene, represents contemporary standard therapy and has extended . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1414325</identifier><identifier>PMID: 25970050</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - secondary ; Adult ; Aged ; Aged, 80 and over ; Cancer therapies ; Chemotherapy ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Double-Blind Method ; Drug Combinations ; Drug therapy ; Evidence-based medicine ; Female ; Humans ; Leukopenia ; Life Sciences ; Male ; Metastases ; Metastasis ; Middle Aged ; Neoplasm Metastasis - drug therapy ; Neutropenia ; Patients ; Proportional Hazards Models ; Survival ; Survival Analysis ; Trifluridine - adverse effects ; Trifluridine - therapeutic use ; Uracil - adverse effects ; Uracil - analogs & derivatives ; Uracil - therapeutic use</subject><ispartof>The New England journal of medicine, 2015-05, Vol.372 (20), p.1909-1919</ispartof><rights>Copyright © 2015 Massachusetts Medical Society. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-c0036a1d615b732977bffbb822d7a5e92010f6ed840292682faba47c0ff6c8eb3</citedby><cites>FETCH-LOGICAL-c534t-c0036a1d615b732977bffbb822d7a5e92010f6ed840292682faba47c0ff6c8eb3</cites><orcidid>0000-0003-4969-2303 ; 0000-0002-3342-397X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1414325$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1680992921?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,777,781,882,2746,2747,26084,27905,27906,52363,54045,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25970050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-rennes.hal.science/hal-01152847$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Mayer, Robert J</creatorcontrib><creatorcontrib>Van Cutsem, Eric</creatorcontrib><creatorcontrib>Falcone, Alfredo</creatorcontrib><creatorcontrib>Yoshino, Takayuki</creatorcontrib><creatorcontrib>Garcia-Carbonero, Rocio</creatorcontrib><creatorcontrib>Mizunuma, Nobuyuki</creatorcontrib><creatorcontrib>Yamazaki, Kentaro</creatorcontrib><creatorcontrib>Shimada, Yasuhiro</creatorcontrib><creatorcontrib>Tabernero, Josep</creatorcontrib><creatorcontrib>Komatsu, Yoshito</creatorcontrib><creatorcontrib>Sobrero, Alberto</creatorcontrib><creatorcontrib>Boucher, Eveline</creatorcontrib><creatorcontrib>Peeters, Marc</creatorcontrib><creatorcontrib>Tran, Ben</creatorcontrib><creatorcontrib>Lenz, Heinz-Josef</creatorcontrib><creatorcontrib>Zaniboni, Alberto</creatorcontrib><creatorcontrib>Hochster, Howard</creatorcontrib><creatorcontrib>Cleary, James M</creatorcontrib><creatorcontrib>Prenen, Hans</creatorcontrib><creatorcontrib>Benedetti, Fabio</creatorcontrib><creatorcontrib>Mizuguchi, Hirokazu</creatorcontrib><creatorcontrib>Makris, Lukas</creatorcontrib><creatorcontrib>Ito, Masanobu</creatorcontrib><creatorcontrib>Ohtsu, Atsushi</creatorcontrib><creatorcontrib>RECOURSE Study Group</creatorcontrib><title>Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations.
Fluoropyrimidines have long represented the cornerstone of treatment for colorectal cancer.
1
Such compounds act primarily as inhibitors of thymidylate synthase, the rate-limiting enzyme in the synthesis of pyrimidine nucleotides.
2
Fluorouracil has been combined with folinic acid (also known as leucovorin) to enhance the capacity of fluorouracil to bind to thymidylate synthase.
2
The addition of irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) to fluorouracil and folinic acid, in combination with either a vascular endothelial growth factor inhibitor (bevacizumab) or an epidermal growth factor inhibitor (e.g., cetuximab or panitumumab) if the tumor contains a wild-type
RAS
gene, represents contemporary standard therapy and has extended . . .</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Drug therapy</subject><subject>Evidence-based medicine</subject><subject>Female</subject><subject>Humans</subject><subject>Leukopenia</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis - drug therapy</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Proportional Hazards Models</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Trifluridine - adverse effects</subject><subject>Trifluridine - therapeutic use</subject><subject>Uracil - adverse effects</subject><subject>Uracil - analogs & derivatives</subject><subject>Uracil - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10c9LwzAUB_Agis7p0asURNBD9b00SdvjGPMXm4LOc0jTBDvaRpNOmH-9HVNBwVwehA9f3g9CjhAuELi4vJ_czZxChiyhfIsMkCdJzBiIbTIAoFnM0jzZI_shLKB_yPJdskd5ngJwGJDrR9WWrqk-TBnNfaXqyNloPnqKEWhknY8ejfVKd86vopnpVOhUV-lo7Grnje56P1atNv6A7FhVB3P4VYfk-WoyH9_E04fr2_FoGmuesC7WAIlQWArkRZrQPE0La4sio7RMFTc5BQQrTJkxoDkVGbWqUCzVYK3QmSmSITnf5L6oWr76qlF-JZ2q5M1oKtd_gMhpxtJ37O3Zxr5697Y0oZNNFbSpa9UatwwSRYZUIO1XNyQnf-jCLX3bT7JWkOd9N-vAeKO0dyF4Y386QJDra8hf1-j98VfqsmhM-aO_19-D0w1omiBbs2j-CfoEJQyMyQ</recordid><startdate>20150514</startdate><enddate>20150514</enddate><creator>Mayer, Robert J</creator><creator>Van Cutsem, Eric</creator><creator>Falcone, Alfredo</creator><creator>Yoshino, Takayuki</creator><creator>Garcia-Carbonero, Rocio</creator><creator>Mizunuma, Nobuyuki</creator><creator>Yamazaki, Kentaro</creator><creator>Shimada, Yasuhiro</creator><creator>Tabernero, Josep</creator><creator>Komatsu, Yoshito</creator><creator>Sobrero, Alberto</creator><creator>Boucher, Eveline</creator><creator>Peeters, Marc</creator><creator>Tran, Ben</creator><creator>Lenz, Heinz-Josef</creator><creator>Zaniboni, Alberto</creator><creator>Hochster, Howard</creator><creator>Cleary, James M</creator><creator>Prenen, Hans</creator><creator>Benedetti, Fabio</creator><creator>Mizuguchi, Hirokazu</creator><creator>Makris, Lukas</creator><creator>Ito, Masanobu</creator><creator>Ohtsu, Atsushi</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-4969-2303</orcidid><orcidid>https://orcid.org/0000-0002-3342-397X</orcidid></search><sort><creationdate>20150514</creationdate><title>Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer</title><author>Mayer, Robert J ; Van Cutsem, Eric ; Falcone, Alfredo ; Yoshino, Takayuki ; Garcia-Carbonero, Rocio ; Mizunuma, Nobuyuki ; Yamazaki, Kentaro ; Shimada, Yasuhiro ; Tabernero, Josep ; Komatsu, Yoshito ; Sobrero, Alberto ; Boucher, Eveline ; Peeters, Marc ; Tran, Ben ; Lenz, Heinz-Josef ; Zaniboni, Alberto ; Hochster, Howard ; Cleary, James M ; Prenen, Hans ; Benedetti, Fabio ; Mizuguchi, Hirokazu ; Makris, Lukas ; Ito, Masanobu ; Ohtsu, Atsushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-c0036a1d615b732977bffbb822d7a5e92010f6ed840292682faba47c0ff6c8eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Drug therapy</topic><topic>Evidence-based medicine</topic><topic>Female</topic><topic>Humans</topic><topic>Leukopenia</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis - drug therapy</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Proportional Hazards Models</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Trifluridine - adverse effects</topic><topic>Trifluridine - therapeutic use</topic><topic>Uracil - adverse effects</topic><topic>Uracil - analogs & derivatives</topic><topic>Uracil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayer, Robert J</creatorcontrib><creatorcontrib>Van Cutsem, Eric</creatorcontrib><creatorcontrib>Falcone, Alfredo</creatorcontrib><creatorcontrib>Yoshino, Takayuki</creatorcontrib><creatorcontrib>Garcia-Carbonero, Rocio</creatorcontrib><creatorcontrib>Mizunuma, Nobuyuki</creatorcontrib><creatorcontrib>Yamazaki, Kentaro</creatorcontrib><creatorcontrib>Shimada, Yasuhiro</creatorcontrib><creatorcontrib>Tabernero, Josep</creatorcontrib><creatorcontrib>Komatsu, Yoshito</creatorcontrib><creatorcontrib>Sobrero, Alberto</creatorcontrib><creatorcontrib>Boucher, Eveline</creatorcontrib><creatorcontrib>Peeters, Marc</creatorcontrib><creatorcontrib>Tran, Ben</creatorcontrib><creatorcontrib>Lenz, Heinz-Josef</creatorcontrib><creatorcontrib>Zaniboni, Alberto</creatorcontrib><creatorcontrib>Hochster, Howard</creatorcontrib><creatorcontrib>Cleary, James M</creatorcontrib><creatorcontrib>Prenen, Hans</creatorcontrib><creatorcontrib>Benedetti, Fabio</creatorcontrib><creatorcontrib>Mizuguchi, Hirokazu</creatorcontrib><creatorcontrib>Makris, Lukas</creatorcontrib><creatorcontrib>Ito, Masanobu</creatorcontrib><creatorcontrib>Ohtsu, Atsushi</creatorcontrib><creatorcontrib>RECOURSE Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayer, Robert J</au><au>Van Cutsem, Eric</au><au>Falcone, Alfredo</au><au>Yoshino, Takayuki</au><au>Garcia-Carbonero, Rocio</au><au>Mizunuma, Nobuyuki</au><au>Yamazaki, Kentaro</au><au>Shimada, Yasuhiro</au><au>Tabernero, Josep</au><au>Komatsu, Yoshito</au><au>Sobrero, Alberto</au><au>Boucher, Eveline</au><au>Peeters, Marc</au><au>Tran, Ben</au><au>Lenz, Heinz-Josef</au><au>Zaniboni, Alberto</au><au>Hochster, Howard</au><au>Cleary, James M</au><au>Prenen, Hans</au><au>Benedetti, Fabio</au><au>Mizuguchi, Hirokazu</au><au>Makris, Lukas</au><au>Ito, Masanobu</au><au>Ohtsu, Atsushi</au><aucorp>RECOURSE Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2015-05-14</date><risdate>2015</risdate><volume>372</volume><issue>20</issue><spage>1909</spage><epage>1919</epage><pages>1909-1919</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations.
Fluoropyrimidines have long represented the cornerstone of treatment for colorectal cancer.
1
Such compounds act primarily as inhibitors of thymidylate synthase, the rate-limiting enzyme in the synthesis of pyrimidine nucleotides.
2
Fluorouracil has been combined with folinic acid (also known as leucovorin) to enhance the capacity of fluorouracil to bind to thymidylate synthase.
2
The addition of irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) to fluorouracil and folinic acid, in combination with either a vascular endothelial growth factor inhibitor (bevacizumab) or an epidermal growth factor inhibitor (e.g., cetuximab or panitumumab) if the tumor contains a wild-type
RAS
gene, represents contemporary standard therapy and has extended . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>25970050</pmid><doi>10.1056/NEJMoa1414325</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-4969-2303</orcidid><orcidid>https://orcid.org/0000-0002-3342-397X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2015-05, Vol.372 (20), p.1909-1919 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01152847v1 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Adult Aged Aged, 80 and over Cancer therapies Chemotherapy Clinical trials Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Double-Blind Method Drug Combinations Drug therapy Evidence-based medicine Female Humans Leukopenia Life Sciences Male Metastases Metastasis Middle Aged Neoplasm Metastasis - drug therapy Neutropenia Patients Proportional Hazards Models Survival Survival Analysis Trifluridine - adverse effects Trifluridine - therapeutic use Uracil - adverse effects Uracil - analogs & derivatives Uracil - therapeutic use |
| title | Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A11%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20Trial%20of%20TAS-102%20for%20Refractory%20Metastatic%20Colorectal%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Mayer,%20Robert%20J&rft.aucorp=RECOURSE%20Study%20Group&rft.date=2015-05-14&rft.volume=372&rft.issue=20&rft.spage=1909&rft.epage=1919&rft.pages=1909-1919&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1414325&rft_dat=%3Cproquest_hal_p%3E3685405121%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1680992921&rft_id=info:pmid/25970050&rfr_iscdi=true |